Mucosal-associated invariant T cells in infectious diseases of respiratory system: recent advancements and applications.

IF 4.4 3区医学 Q2 IMMUNOLOGY

Journal of Inflammation-London Pub Date : 2024-02-28 DOI:10.1186/s12950-024-00376-z

Xue Lin, Ye Wang, Yanqi He

引用次数: 0

Abstract

Mucosal-associated invariant T (MAIT) cells are an atypical subset of T lymphocytes, which have a highly conserved semi-constant αβ chain of T-cell receptor (TCR) and recognize microbe-derived vitamin B metabolites via major histocompatibility complex class I related-1 molecule (MR1). MAIT cells get activated mainly through unique TCR-dependent and TCR-independent pathways, and express multiple functional and phenotypic traits, including innate-like functionality, T helper (Th) 1 cell immunity, Th 17 cell immunity, and tissue homing. Given the functions, MAIT cells are extensively reported to play a key role in mucosal homeostasis and infectious diseases. In the current work, we review the basic characteristics of MAIT cells and their roles in mucosal homeostasis and development of respiratory infectious diseases as well as their potential therapeutic targets.

查看原文本刊更多论文

呼吸系统感染性疾病中的粘膜相关不变性 T 细胞：最新进展与应用。

粘膜相关不变T细胞（MAIT）是T淋巴细胞的一个非典型亚群，具有高度保守的半不变T细胞受体（TCR）αβ链，通过主要组织相容性复合体I类相关-1分子（MR1）识别微生物衍生的维生素B代谢物。MAIT 细胞主要通过独特的 TCR 依赖性和 TCR 非依赖性途径被激活，并表现出多种功能和表型特征，包括先天类功能、T 辅助（Th）1 细胞免疫、Th 17 细胞免疫和组织归巢。鉴于这些功能，MAIT 细胞被广泛报道在粘膜平衡和感染性疾病中发挥关键作用。在目前的研究中，我们回顾了 MAIT 细胞的基本特征及其在粘膜稳态和呼吸道感染性疾病发展中的作用，以及其潜在的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Inflammation-London IMMUNOLOGY-

CiteScore

7.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Journal of Inflammation welcomes research submissions on all aspects of inflammation. The five classical symptoms of inflammation, namely redness (rubor), swelling (tumour), heat (calor), pain (dolor) and loss of function (functio laesa), are only part of the story. The term inflammation is taken to include the full range of underlying cellular and molecular mechanisms involved, not only in the production of the inflammatory responses but, more importantly in clinical terms, in the healing process as well. Thus the journal covers molecular, cellular, animal and clinical studies, and related aspects of pharmacology, such as anti-inflammatory drug development, trials and therapeutic developments. It also considers publication of negative findings. Journal of Inflammation aims to become the leading online journal on inflammation and, as online journals replace printed ones over the next decade, the main open access inflammation journal. Open access guarantees a larger audience, and thus impact, than any restricted access equivalent, and increasingly so, as the escalating costs of printed journals puts them outside University budgets. The unrestricted access to research findings in inflammation aids in promoting dynamic and productive dialogue between industrial and academic members of the inflammation research community, which plays such an important part in the development of future generations of anti-inflammatory therapies.